Avalyn Pharma Inc. has set the price for its upsized initial public offering at $18.00 per share, offering 16,666,667 shares of common stock. The transaction is expected to generate gross proceeds of $300 million before the deduction of underwriting discounts, commissions and offering expenses.
The clinical-stage biopharmaceutical company has also granted the underwriters a 30-day option to acquire up to 2,500,000 additional shares at the IPO price, less underwriting discounts and commissions. The company is the seller of all shares in the offering.
Trading of Avalyn's common stock on the Nasdaq Global Select Market is expected to begin on April 30, 2026 under the ticker symbol "AVLN." The offering is anticipated to close on May 1, 2026, subject to customary closing conditions.
Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities are listed as joint book-running managers for the offering. A registration statement related to the offering was filed with the Securities and Exchange Commission and was declared effective on April 29, 2026.
Business focus and clinical programs
Avalyn describes itself as a company focused on developing inhaled therapies for serious, rare respiratory diseases. The firm is advancing several clinical programs aimed at delivering lung-targeted formulations of established antifibrotic agents.
Its AP01 program is an inhaled formulation of pirfenidone that is being evaluated in a global Phase 2b clinical trial for patients with progressive pulmonary fibrosis. The AP02 program is an inhaled formulation of nintedanib currently in a global Phase 2 trial for patients with idiopathic pulmonary fibrosis.
In addition, Avalyn is developing AP03, an inhaled combination therapy that pairs pirfenidone and nintedanib. AP03 is designed to deliver dual antifibrotic mechanisms through a single lung-targeted platform.
Market and timing details
The pricing and planned Nasdaq listing provide a timetable for Avalyn's entry into the public markets, with the registration statement declared effective on April 29, 2026 and trading expected to commence the following day. The company has structured the offering so that all shares are being offered by Avalyn itself, and has provided the underwriters with a standard option to purchase additional shares to cover over-allotments.
Additional context and limitations
All details above are drawn from the company announcement of the offering and from the related registration materials. No information beyond what Avalyn disclosed has been added. The planned trading date, closing date and underwriting arrangements are subject to customary closing conditions as stated by the company.